TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year and an insulin infusion pump for at least 6 months~* Age 3 to \<15 years~* HbA1c \<=8.5%~* Availability of internet access for periodic upload of study data~Exclusion Criteria:~* Diabetic ketoacidosis in the past 3 months~* Hypoglycemic seizure or loss of consciousness in past 6 months~* History of seizure disorder (except for hypoglycemic seizures)~* Cystic fibrosis~* Current use of oral/inhaled glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study~* History of ongoing renal disease (other than microalbuminuria), or liver disease (Creatinine is \> 1.5 mg/dL (132 µmol/L))~* Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as:~  * Inpatient psychiatric treatment in the past 6 months~ * Uncontrolled adrenal disorder~ * Abuse of alcohol~* Pregnancy~* Liver disease as defined by an Alanine Aminotransferase Test (ALT) greater than 3 times the upper limit of normal

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Pump suspension algorithm (Type: ACTIVE_COMPARATOR): The pump suspension algorithm will be running actively on the study laptop during the night and suspend the pump if the algorithm predicts hypoglycemia.
- Standard of Care (Type: NO_INTERVENTION): The control algorithm will run passively and not suspend the patient's pump.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be scheduled for a catheter ablation procedure for non-valvular atrial fibrillation (NVAF);~* Have a documented history of paroxysmal (lasting \<1 week) or persistent (lasting \>1 week and \<1 year or requiring pharmacological or electrical cardioversion), or long standing persistent (\>=1 year) NVAF;~* Be suitable for anticoagulant therapy and catheter ablation as per the judgment of the investigator;~* Women must be postmenopausal before entry or practicing a highly effective method of birth control when heterosexually active;~* Women of childbearing potential must have a negative serum pregnancy test at screening;~* Be willing and able to adhere to the prohibitions and restrictions specified in the study protocol;~* Have a life expectancy of at least 6 months~Exclusion Criteria:~* Has a history of a prior stroke, transient ischemic attack (TIA) or non-convulsive status epilepticus within 6 months of the screening visit;~* Has a history of a major bleeding or thromboembolic event within the 12 months immediately preceding the catheter ablation procedure;~* Has had major surgery (requiring general anesthesia), within 6 months before screening or planned surgery during the time the subject is expected to participate in the study;~* Has NVAF due to electrolyte imbalance, hyperthyroidism, or other reversible or noncardiac cause of NVAF;~* Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rivaroxaban (Type: EXPERIMENTAL): rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
- vitamin K antagonist (VKA) (Type: EXPERIMENTAL): dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Completed double-blind portion of the IM101064 study.~* Rheumatoid arthritis (RA) for greater than 1 year from the time of initial diagnosis~* American College of Rheumatology (ACR) functional class I, II, III~* Subjects currently or previously received an anti-TNF therapy at an approved labeled dose for at least 3 months~Exclusion Criteria:~* Subjects with active vasculitis of a major organ system (except subcutaneous rheumatoid nodules)~* History of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by local resection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label Abatacept (ABA)-Previous User (Type: EXPERIMENTAL): In participants who have had an inadequate efficacy response or intolerance on previous TNF-antagonist therapy (off therapy for at least 2 months), open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
- Open-label ABA-Current User (Type: EXPERIMENTAL): In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing \< 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \> 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
- Long-term ABA (Type: EXPERIMENTAL): Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Post-Stroke Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Stroke within the last 120 days~Exclusion Criteria:~* DSM (Diagnostic and Statistical Manual) IV criteria for major or minor depressive disorder~* Heart, respiratory, kidney, or liver failure; severely disabling musculoskeletal disorder; or cancer~* Diagnosis of neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Multiple System Atrophy, or Huntington's disease~* Pre-existing dementia or aphasia with severe language comprehension deficits~* Alcohol or substance abuse or dependence within the last 12 months~* Recurrent unipolar or bipolar disorder prior to the stroke

- Gender: ALL
- Minimum Age: 31 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- 1 Problem Solving Therapy (Type: EXPERIMENTAL): Participants will receive problem solving therapy.
- 2. Escitalopram (Type: EXPERIMENTAL): Participants will receive escitalopram.
- 3 Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Catheter Thread Between Two Different Vendors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: women in labor~-~Exclusion Criteria:~* none

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arrow Catheter Kit. (Type: OTHER): Arrow FlexTip Plus Epidural Catheterization Kit is a single orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
- B.Braun Catheter Kit (Type: OTHER): Perifix FX Springwound Epidural Catheter Kit is a multi-orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Bolus of 10 µg/kg of Alfentanil on the Pupillary Pain Index

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Elective surgery under general anesthesia~* Written informed consent~Exclusion Criteria:~* Chronic pain~* Preoperative analgesic drug~* Neurologic disease~* Ophtalmic disease

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- alfentanil (Type: EXPERIMENTAL): Children under general anesthesia for elective surgery. Induction with sevoflurane or propofol according to the preference of the patient.~Maintenance with sevoflurane. 5 minutes before skin incision, first assessment of the pupillary pain index. Then injection of 10 µg/kg of alfentanil. After 5 minutes second assessment of pupillary pain index. End of study period, beginning of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Erectile Dysfunction (ED) patient who has newly been prescribed vardenafil (Levitra film-coated tablet) in accordance with the terms of the local marketing authorization.~* Diagnosis of erectile dysfunction at the discretion of the physician, based on the patients ED history.~* No use of any Phosphodiesterase Type 5 (PDE5) inhibitor within 1 month of study entry.~* Documented Metabolic Syndrome (MetS), preferably according to the definition of the International Diabetes Foundation.~Exclusion Criteria:~* Do not follow the contraindications and warnings of the Summary of Product Characteristics.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient requires autografting for treatment of an acute full-thickness skin defect (e.g., trauma- or surgery-related).~2. The maximum area requiring autografting is 50% Total Body Surface Area (TBSA).~3. Two comparable areas requiring autografting, each at least 160 cm2 (or 320 cm2 contiguous), excluding face and genitalia. When hands or joints are included in the treatment areas, comparability of treatment areas means that each area (RECELL and Control) must include the same contralateral joint and/or hand.~4. The patient is at least 5 years of age.~5. The patient (or parent/guardian) is willing and able to comply with all compulsory study procedures and visit schedule.~6. The patient agrees to abstain from any other treatment (e.g., external fixation) of the study treatment areas for the duration of his/her participation the study (1 year).~7. The patient agrees to abstain from enrollment in any other interventional clinical trial for the duration of his/her participation the study (1 year).~8. In the opinion of the investigator, the patient and/or guardian must be able to:~   1. Understand the full nature and purpose of the study, including possible risks and adverse events,~  2. Understand instructions, and~  3. Provide voluntary informed written consent.~Exclusion Criteria:~1. Not able to understand English or Spanish.~2. The area requiring autografting sustained a burn injury.~3. The treatment area has previously failed to heal subsequent to surgical intervention for closure.~4. The patient is unable to follow the protocol requirements.~5. The patient has a condition that in the investigator's opinion may compromise patient safety or trial objectives.~6. Current use of medications that in the investigator's opinion may compromise patient safety or trial objectives.~7. The patient has a known hypersensitivity to trypsin or compound sodium lactate for irrigation (Hartmann's) solution.~8. The patient is pregnant or breast-feeding (pregnancy test should be performed in accordance with local institutional requirements).~9. Life expectancy is less than 1 year.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Participants (within patient control) (Type: EXPERIMENTAL): Each participant will serve as their own Control, receiving both Control and Investigational Interventions randomly allocated to treatment of a portion of a full-thickness skin defect.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-metastatic biopsy-proven clear cell renal cell carcinoma (T2-T3N0-1M0)~* Schedule to undergo either partial or radical nephrectomy as part of treatment plan~* ECOG performance status of 0 or 1~* Adequate organ and marrow function defined by study-specified laboratory tests~* Agree to comply with scheduled visits, treatment plans, lab tests and other study procedures~* Do not have any other cancers in the 5 yr preceding diagnosis of their renal cancer~Exclusion Criteria:~* Patients who have received other systems for anti-tumor treatment~* Patients who have previously received targeted or immunotherapy~* Need for urgent or emergent nephrectomy to relieve symptoms~* Current use of immunosuppressive agents~* Pregnant or breastfeeding women~* History of autoimmune disease or syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant arm (Type: EXPERIMENTAL): Patients will receive axitinib 5 mg bid combined with Toripalimab 3mg/KG q3w for up to 12 wk.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV-TR documented bipolar I or bipolar II, most recent episode depressed~* Outpatient status as enrollment~Exclusion Criteria:~* Other than bipolar disorder under study, patients must not have another current, major disorder that is symptomatic or has required treatment within 6 months of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine Immediate Release (IR) (Type: ACTIVE_COMPARATOR): Quetiapine 25, 100, 200 and 300 mg
- Quetiapine Extended Release (XR) (Type: ACTIVE_COMPARATOR): Quetiapine 50, 200, 300

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Unmodulated 5 Kilohertz Currents Versus TENS: Effect on Pain Thresholds, Tactile Threshold, and Nerve Conduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants will be volunteer healthy students of Physiotherapy, University of Castilla - La Mancha, older than 18 years.~Exclusion Criteria:~* Neuromuscular disease.~* Epilepsy.~* Trauma, surgery or pain affecting the upper limb, shoulder girdle or cervical area.~* Osteosynthesis material in the upper limb.~* Diabetes.~* Cancer.~* Cardiovascular disease.~* Pacemaker or other implanted electrical device.~* Take any drug (NSAIDs, corticosteroids, antidepressants, analgesics, antiepileptics, ...) during the study and in the previous 7 days.~* Presence of tattoos or other external agent introduced into the treatment or assessment area.~* Pregnancy.~* Sensitivity disturbance in upper limb.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- 5 KHz (Type: EXPERIMENTAL): Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold.
- TENS (Type: EXPERIMENTAL): Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 110 Hz and pulse width 200 microseconds
- Sham Stimulation (Type: SHAM_COMPARATOR): Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Pre-operative eligibility:~* Patients above the age of 18, no upper age limit~* English-speaking~* Delayed reconstruction (mastectomy already performed) or immediate reconstruction (mastectomy at the same time as reconstruction)~* Reconstruction using abdominal tissues including free MS-TRAM or DIEP~Exclusion Criteria:~* Patient refusal~* Inability to give informed consent~* BMI \> 40~* Allergy to Bupivacaine~* Known cardiac or liver disease (contraindicated for Bupivacaine use)~* Patients who will undergo any of the following:~  * Implant breast reconstruction~ * Combined implant and autologous tissue reconstruction~ * Non-abdominally based autologous tissue reconstruction~ * Nonmicrosurgical abdominally based breast reconstruction (pedicled TRAM flap)~* Drug addiction~* Opioid tolerance defined as preoperative opioid use of \>50 mg PO morphine equivalent~* Psychiatric illness

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isotonic saline (control group) (Type: PLACEBO_COMPARATOR): At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
- Bupivacaine (study group) (Type: EXPERIMENTAL): At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete